Calcium channel antagonists augment hydroxyurea- and RU486-induced inhibition of meningioma growth in vivo and in vitro

Neurosurgery

Volumn 59, Issue 5, 2006, Pages 1109-1120

  Ragel, Brian T ^a,b   Gillespie, David L ^b   Kushnir, Vitaly ^b   Polevaya, Nika ^b   Kelly, David ^b   Jensen, Randy L ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Calcium channel antagonists; Diltiazem; Hydroxyurea; Meningioma; Mifepristone; Verapamil

Indexed keywords

ANTIGESTAGEN; BLOOD CLOTTING FACTOR 8; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; HYDROXYUREA; KI 67 ANTIGEN; MIFEPRISTONE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INDICATION; DRUG POTENTIATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INOPERABLE CANCER; MENINGIOMA; MICROSCOPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CALCIUM CHANNEL BLOCKERS; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYUREA; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MICE; MICE, NUDE; MIDDLE AGED; MIFEPRISTONE; TUMOR CELLS, CULTURED;

EID: 33845210745     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000245597.46581.FB     Document Type: Article

References (66)

1. al-Mefty O, Kadri PA, Pravdenkova S, Sawyer JR, Stangeby C, Husain M: Malignant progression in meningioma: Documentation of a series and analysis of cytogenetic findings. J Neurosurg 101:210-218, 2004.
2. al-Rodhan NR, Laws ER Jr: Meningioma: Ahistorical study of the tumor and its surgical management. Neurosurgery 26:832-847, 1990.
3. al-Rodhan RF, Laws ER Jr: The history of intracranial meningiomas, in al-Mefty O (ed): Meningiomas. New York, Raven Press, 1991, pp 1-6.
4. Barnett GH, Suh JH, Crownover RL: Recent advances in the treatment of skull base tumors using radiation. Neurosurg Clin N Am 11:587-596, 2000.
5. Batra S, Popper LD, Hartley-Asp B: Effect of calcium and calcium antagonists on 45Ca influx and cellular growth of human prostatic tumor cells. Prostate 19:299-311, 1991.
6. Bertrand V, Bastie MJ, Vaysse N, Pradayrol L: Inhibition of gastrin-induced proliferation of AR4-2J cells by calcium channel antagonists. Int J Cancer 56:427-432, 1994.
7. Deletd in proof.
8. Blankenstein MA, van der Meulen, Dijk C, Thijssen JH: Assay of oestrogen and progestin receptors in human meningioma cytosols using immunological methods. Clin Chim Acta 165:189-195, 1987.
9. Bowles AP Jr, Pantazis CG, Wansley W: Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: An in vitro and in vivo study. J Neurosurg 73:248-253, 1990.
10. Cahill DW, Bashirelahi N, Solomon LW, Dalton T, Salcman M, Ducker TB: Estrogen and progesterone receptors in meningiomas. J Neurosurg 60:985-993, 1984.
11. Cano-Gauci DF, Riordan JR: Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation. Biochem Pharmacol 36:2115-2123, 1987.
12. Carroll RS, Glowacka D, Dashner K, Black PM: Progesterone receptor expression in meningiomas. Cancer Res 53:1312-1316, 1993.
13. Chamberlain MC, Tsao-Wei DD, Groshen S: Temozolomide for treatment-resistant recurrent meningioma. Neurology 62:1210-1212, 2004.
14. DeMonte F: Current management of meningiomas. Oncology 9:83-91, 96, 99-101, 1995.
15. Fardel O, Courtois A, Drenou B, Lamy T, Lecureur V, le Prise PY, Fauchet R: Inhibition of P-glycoprotein activity in human leukemic cells by mifepristone. Anticancer Drugs 7:671-677, 1996.
16. Fuentes S, Chinot O, Dufour H, Paz-Paredes A, Metellus P, Barrie-Attarian M, Grisoli F: Hydroxyurea treatment for unresectable meningioma [in French]. Neurochirurgie 50:461-467, 2004.
17. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT: The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 54:6167-6175, 1994.
18. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT: The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 54:6167-6175, 1994.
19. Gillo B, Ma YS, Marks AR: Calcium influx in induced differentiation of murine erythroleukemia cells. Blood 81:783-792, 1993.
20. Goldsmith BJ, Larson DA: Conventional radiation therapy for skull base meningiomas. Neurosurg Clin N Am 11:605-615, 2000.
21. Goldsmith BJ, Wara WM, Wilson CB, Larson DA: Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 80:195-201, 1994.
22. Grunberg SM: Role of antiprogestational therapy for meningiomas. Hum Reprod 9 [Suppl 1]:202-207, 1994.
23. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L, Stevenson LL: Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74:861-866, 1991.
24. Helson L: Calcium channel blocker enhancement of anticancer drug cytotoxicity: A review. Cancer Drug Deliv 1:353-361, 1984.
25. Ince P, Appleton DR, Finney KJ, Sunter JP, Watson AJ: Verapamil increases the sensitivity of primary human colorectal carcinoma tissue to vincristine. Br J Cancer 53:137-139, 1986.
26. Jensen RL, Lee YS, Guijrati M, Origitano TC, Wurster RD, Reichman OH: Inhibition of in vitro meningioma proliferation after growth factor stimulation by calcium channel antagonists: Part II - Additional growth factors, growth factor receptor immunohistochemistry, and intracellular calcium measurements. Neurosurgery 37:937-947, 1995.
27. Jensen RL, Leppla D, Rokosz N, Wurster RD: Matrigel augments xenograft transplantation of meningioma cells into athymic mice. Neurosurgery 42:130-136, 1998.
28. Jensen RL, Origitano TC, Lee YS, Weber M, Wurster RD: In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists. Neurosurgery 36:365-374, 1995.
29. Jensen RL, Petr M, Wurster RD: Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation. Neurosurgery 46:692-703, 2000.
30. Jensen RL, Wurster RD: Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice. Surg Neurol 55:275-283, 2001.
31. Kennedy BJ, Yarbro JW: Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia. JAMA 195:1038-1043, 1966.
32. Kohn EC, Liotta LA: L651582: A novel antiproliferative and antimetastasis agent. J Natl Cancer Inst 82:54-60, 1990.
33. Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B, Liotta LA: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56:569-573, 1996.
34. Kvasnicka HM, Thiele J, Staib P, Schmitt-Graeff A, Griesshammer M, Klose J, Engels K, Kriener S: Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 103:3549-3551, 2004.
35. Kyritsis AP: Chemotherapy for meningiomas. J Neurooncol 29:269-272, 1996.
36. Lecureur V, Fardel O, Guillouzo A: The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett 355:187-191, 1994.
37. Lee WH: Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery 27:389-396, 1990.
38. Levine ZT, Buchanan RI, Sekhar LN, Rosen CL, Wright DC: Proposed grading system to predict the extent of resection and outcomes for cranial base meningiomas. Neurosurgery 45:221-230, 1999.
39. Li A, Felix JC, Minoo P, Amezcua CA, Jain JK: Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells. Fertil Steril 84:202-211, 2005.
40. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ: Meningiomas, in Kleihues P, Cavenee WK (eds): World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of the Nervous System. Lyon, IARC Press, 2000, pp 134-141.
41. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE: Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97:341-346, 2002.
42. Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T: Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 80:527-534, 1994.
43. Maurer-Schultze B, Siebert M, Bassukas ID: An in vivo study on the synchronizing effect of hydroxyurea. Exp Cell Res 174:230-243, 1988.
44. Merry S, Fetherston CA, Kaye SB, Freshney RI, Plumb JA: Resistance of human glioma to adriamycin in vitro: The role of membrane transport and its circumvention with verapamil. Br J Cancer 53:129-135, 1986.
45. Metcalfe JC, Moore JP, Smith GA, Hesketh TR: Calcium and cell proliferation. Br Med Bull 42:405-412, 1986.
46. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RGG, Martuza RL: Meningioma: Analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62:18-24, 1985.
47. Newman SA: Meningiomas: A quest for the optimum therapy. J Neurosurg 80:191-194, 1994.
48. Newton HB, Scott SR, Volpi C: Hydroxyurea chemotherapy for meningiomas: Enlarged cohort with extended follow-up. Br J Neurosurg 18:495-499, 2004.
49. Newton HB, Slivka MA, Stevens C: Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 49:165-170, 2000.
50. Olson JJ, Beck DW, Schlechte JA, Loh PM: Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. J Neurosurg 66:584-587, 1987.
51. Ragel B, Jensen RL: New approaches for the treatment of refractory meningiomas. Cancer Control 10:148-158, 2003.
52. Ragel B, Jensen RL: Pathophysiology of meningiomas. Semin Neurosurg 14:169-185, 2004.
53. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT: Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: Potential therapeutic application. J Neurosurg 103:508-517, 2005.
54. Robinson BA, Clutterbuck RD, Millar JL, McElwain TJ: Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow. Br J Cancer 52:813-822, 1985.
55. Rutka JT, Giblin J, Dougherty DV, McCulloch JR, DeArmond SJ, Rosenblum ML: An ultrastructural and immunocytochemical analysis of leptomeningeal and meningioma cultures. J Neuropathol Exp Neurol 45:285-303, 1986.
56. Sartippour MR, De Leon E, Rubio R, Brooks MN: The effect of commonly used drugs on angiogenesis. Anticancer Res 23:231-234, 2003.
57. Schmidt WF, Huber KR, Ettinger RS, Neuberg RW: Antiproliferative effect of verapamil alone on brain tumor cells in vitro. Cancer Res 48:3617-3621, 1988.
58. Schrell UM, Rittig MG, Anders M, Kiesewetter F, Marschalek R, Koch UH, Fahlbusch R: Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 86:845-852, 1997.
59. Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, Fahlbusch R: Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86:840-844, 1997.
60. Schrell UM, Rittig MG, Koch U, Marschalek R, Anders M: Hydroxyurea for treatment of unresectable meningiomas. Lancet 348:888-889, 1996.
61. Taylor JM, Simpson RU: Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res 52:2413-2418, 1992.
62. Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y: Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 43:2905-2910, 1983.
63. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972, 1981.
64. Verschraegen CF, Mendoza JT, Kozielski AJ, Giovanella BC: Modulation of the response to chemotherapy in a human melanoma clone by the site of growth in the nude mouse. Anticancer Res 15:9-11, 1995.
65. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991.
66. Yohem KH, Clothier JL, Montague SL, Geary RJ, Winters AL 3rd, Hendrix MJ, Welch DR: Inhibition of tumor cell invasion by verapamil. Pigment Cell Res 4:225-233, 1991.